Conference Coverage
Conference Coverage
Anti-BCL2, CD20 combo safe, effective in untreated CLL
Key clinical point: Patients with CLL and comorbidities were able to tolerate an experimental regimen of obinutuzumab and venetoclax. Major...
Conference Coverage
Triplet disappoints in follicular lymphoma trial
Photo courtesy of ASH ORLANDO, FL—A 3-drug regimen is likely not worth pursuing as a first-line treatment option for follicular lymphoma (FL),...
Conference Coverage
ASH: Idelalisib plus standard therapy boosts survival in relapsed CLL
Adding idelalisib to bendamustine and rituximab therapy significantly improved survival in relapsed/refractory chronic lymphocytic leukemia.
Conference Coverage
ASH: First-line ibrutinib beats standard chemo for CLL/SLL in older patients
First-line ibrutinib significantly extends survival in older patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma,...
Conference Coverage
ASH: Donor CAR-T cells elicit responses in mixture of progressive B-cell cancers
Key clinical point: Allogeneic anti-CD19 CAR T-cell therapy showed promise in a treatment approach for B-cell malignancies persisting after...
Conference Coverage
ITC 2015: Review IDs features to aid thyroid lymphoma diagnosis
Rapidly enlarging thyroid masses with compressive symptoms may signal thyroid lymphoma, according to findings from a review of cases at the Mayo...
Conference Coverage
Lupus and diffuse large B-cell lymphoma share genetic risk
Key clinical point: Two genetic risk variants for systemic lupus erythematosus also were clearly linked to risk of diffuse large B-cell lymphoma...
Conference Coverage
New therapies finding their place in management of follicular lymphoma
Conference Coverage
Reprogramming the immune system
showing Hodgkin lymphoma NEW YORK—Using a 3-pronged approach to reprogram the immune system—inhibition of critical pathways, activation of others...
Conference Coverage
MHM: Novel agents, combos show promise for relapsed/refractory CLL
Novel agents and combinations are showing great promise in relapsed/refractory CLL.